Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

NCT01852266 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

NIH

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: RSV cps2 Vaccine
BIOLOGICAL: Placebo Vaccine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)